FATE – fate therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Fate Therapeutics, Inc. (NASDAQ: FATE) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $6.00 price target on the stock, up previously from $4.00.
FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the Firm
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target lowered by analysts at HC Wainwright from $7.00 to $5.00. They now have a "neutral" rating on the stock.
Form 4 FATE THERAPEUTICS INC For: Jun 07 Filed by: Lee Michael Stewart
Form 4 FATE THERAPEUTICS INC For: Jun 07 Filed by: Redmile Group, LLC
Form 4 FATE THERAPEUTICS INC For: Jun 07 Filed by: RASTETTER WILLIAM H
Form 4 FATE THERAPEUTICS INC For: Jun 07 Filed by: COUGHLIN TIMOTHY
Form 4 FATE THERAPEUTICS INC For: Jun 07 Filed by: Jooss Karin
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.